Luis P. M.
- Country
- Spain
- Department
- Pneumology
Research Overview
- Long-term safety and efficacy of subcutaneous lunsekimig in adults with asthma: An open-label extension study
- A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma
- Long-term Safety and Tolerability Evaluation of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Data & Insights
Has run more than one trial at 371 of 644 partner sites.
Specializations
Respiratory Disease Management
The investigator specializes in treating various respiratory conditions, with particular emphasis on Chronic Obstructive Pulmonary Disease (COPD) and its management in moderate to severe cases. Their work extends to evaluating novel therapeutic approaches for COPD exacerbations.
- COPD Treatment Innovation
- Exacerbation Management
- Respiratory Function Assessment
Pulmonary Fibrosis Expertise
Focused on advancing treatments for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. The investigator evaluates innovative therapeutic interventions aimed at improving lung function and patient outcomes.
- Fibrotic Lung Disease Treatment
- Interstitial Lung Disease Management
- Systemic Sclerosis-Associated Lung Conditions
Asthma and Bronchiectasis Studies
The investigator focuses on developing treatments for moderate to severe uncontrolled asthma and non-cystic fibrosis bronchiectasis. Their work includes evaluation of novel therapeutic agents for respiratory conditions.
- Asthma Control Optimization
- Bronchiectasis Management
- Pulmonary Exacerbation Prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.